Skip to main content
Douglas Losordo, MD, Cardiology, New York, NY

DouglasWLosordoMD

Cardiology New York, NY

Executive Vice President, Global Head of R&D, Chief Medical Officer.

Dr. Losordo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Losordo's full profile

Already have an account?

  • Office

    420 Lexington Ave
    New York, NY 10011

Education & Training

  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterResidency, Internal Medicine, 1983 - 1986
  • University of Vermont College of Medicine
    University of Vermont College of MedicineClass of 1983
  • St Elizabeth's Medical Center
    St Elizabeth's Medical CenterFellowship, Cardiovascular Disease

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2014 - 2025
  • IL State Medical License
    IL State Medical License 2007 - 2020
  • MA State Medical License
    MA State Medical License 1984 - 2019
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Super Doctor SuperDoctors.com
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer
    Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical OfficerNovember 17th, 2020
  • AHA: Caladrius Single Injection Helps Heart Disease That Hits Women the Hardest
    AHA: Caladrius Single Injection Helps Heart Disease That Hits Women the HardestNovember 18th, 2019
  • Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
    Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019November 16th, 2019
  • Join now to see all

Grant Support

  • Small Animal Surgery And HistologyNational Heart, Lung, And Blood Institute2012
  • Role Of PAI-1 In Cardiovascular Repair And FibrosisNational Heart, Lung, And Blood Institute2012
  • Peptide Amphiphiles To Augment Progentitor Cell TherapiesNational Heart, Lung, And Blood Institute2012
  • Mitochondrial Defects In Epcs In Diabetes And AgingNational Heart, Lung, And Blood Institute2012
  • FACS Analysis And Cell SortingNational Heart, Lung, And Blood Institute2012
  • Epigenetic Modulation Of EPC For CardiomyogenesisNational Heart, Lung, And Blood Institute2012
  • Advanced Molecular ImagingNational Heart, Lung, And Blood Institute2012
  • Administrative CoreNational Heart, Lung, And Blood Institute2012
  • Therapeutic Angiogenesis In Vascular Medicine IVNational Heart, Lung, And Blood Institute2011
  • Novel Approaches To Ischemic Tissue RepairNational Heart, Lung, And Blood Institute2011
  • Cardiovascular Regenerative MedicineNational Heart, Lung, And Blood Institute2011
  • Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2011
  • Therapeutic Angiogenesis In Vascular Medicine IIINational Heart, Lung, And Blood Institute2009–2010
  • Novel Approaches To Ischemic Tissue RepairNational Heart, Lung, And Blood Institute2009–2010
  • Role Of Progenitor Cells In Cardiovascular MedicineNational Heart, Lung, And Blood Institute2007–2010
  • Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2007–2010
  • Progenitor Cells In Vascular BiologyNational Heart, Lung, And Blood Institute2007–2008
  • Restenosis And Endothelial ProliferationNational Heart, Lung, And Blood Institute2007
  • Role Of Progenitor Cells In Cardiovascular MedicineNational Heart, Lung, And Blood Institute2006
  • Autologous CD34+ Cell Therapy For Therapeutic Angiogenesis In Advanced PADNational Heart, Lung, And Blood Institute2006
  • Progenitor Cells In Vascular BiologyNational Heart, Lung, And Blood Institute2005–2006
  • Restenosis And Endothelial ProliferationNational Heart, Lung, And Blood Institute1999–2006
  • VEGF Gene Transfer To Prevent Coronary Artery RestenosisNational Heart, Lung, And Blood Institute2001–2005
  • Core--TrainingNational Heart, Lung, And Blood Institute2001–2005
  • Therapeutic Angiogenesis In Vascular Medicine IINational Heart, Lung, And Blood Institute2002–2004
  • Center Of Excellence In Gene Therapy(Program Project)National Heart, Lung, And Blood Institute2002–2004
  • Re-Endothelialization And Restenosis IINational Heart, Lung, And Blood Institute2001–2004
  • Estrogen, Angiogenesis And Endothelial Progenitor CellsNational Heart, Lung, And Blood Institute2001–2004
  • Estrogen For Prevention Of Restenosis In Older WomenNational Institute On Aging1999–2000

Professional Memberships